Related Experiment Video
Updated: Jun 25, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Hydroxysafflor Yellow A Promotes Lac-Phe Synthesis to Suppress GIP and Ameliorate Obesity in DIO Mice
Wenjing Hu1,2, Kemin Yan1, Xiaorui Lyu1
1Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Abstract:
Hydroxysafflor Yellow A (HSYA), the main active component of Carthamus tinctorius L., has been shown to reduce feeding efficiency and diet-induced obesity (DIO) by inhibiting GIP secretion. This study aimed to clarify the detailed mechanism through which HSYA suppresses GIP production. Diet-induced obese mice were treated with HSYA or HSYA plus antibiotics. A combination of untargeted and targeted metabolomics was performed on cecal contents to identify differential metabolites. RT-qPCR and siRNA knock down experiments were performed in mouse intestinal tissues, Caco-2 and STC-1 cells for further exploring the role of HSYA in regulating differential metabolites and its possible mechanism. HSYA could effectively reduce bodyweight and improve glucolipid metabolism in DIO mice. HSYA treatment significantly elevated N-lactoyl-phenylalanine (Lac-Phe) levels in the cecum, but not in the serum, independent of gut microbiota alterations. Carnosine dipeptidase II (CNDP2), the sole enzyme responsible for Lac-Phe production, was also upregulated by HSYA treatment in intestinal tissues and Caco-2 cells and this effect was abolished by CNDP2 knockdown. Furthermore, Lac-Phe treatment could directly inhibit GIP production in STC-1 cells. Our findings firstly revealed a host-derived pathway through which HSYA suppresses GIP production by the upregulation of CNDP2 expression and increasing Lac-Phe synthesis. This novel mechanism provided new insights into the metabolic regulation of GIP and highlights the therapeutic potential of HSYA in treatment of obesity.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors

